Banyu And Santen To Co-promote Glaucoma Combo Drug
This article was originally published in PharmAsia News
Merck Japanese subsidiary Banyu Pharmaceutical and ophthalmology specialty drug maker Santen Pharmaceutical Feb. 2 signed an agreement to co-promote glaucoma combination drug of Truspot (dorzolamide)/Timoptol (timolol maleate)
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.